Navigation Links
Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Date:2/9/2011

ore study entry.  Patients enrolled in this study need not have a genetic mutation responsive to Amigal as a monotherapy.  Each patient will receive ERT alone and then ERT after administration of a single oral dose of Amigal.  There will be two cohorts of nine patients treated with one of two Amigal dose levels.

The primary outcome measure will be a comparison of the ERT activity in plasma and safety and tolerance with and without coadministration of Amigal.  The effect of co-administration of ERT on the pharmacokinetics and safety of Amigal will also be evaluated.  A secondary outcome measure includes distribution of the ERT to skin.  Other outcome measures include evaluating the effect of co-administration of Amigal and ERT on GL-3 levels in skin and GL-3 excretion in urine.  Amicus expects results from this study to be available in the second half of 2011.

Approximately five clinical sites will participate in this trial in the United States and in Europe.

About Amigal

On October 29, 2010, Amicus announced a definitive agreement with GSK to develop and commercialize Amigal (migalastat HCl), currently in Phase 3, for the treatment of Fabry disease as a monotherapy. Under the terms of the agreement, GSK received an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl. As part of the agreement, GSK and Amicus also intend to investigate Amigal as a potential treatment for Fabry disease when co-administered with ERT.  

The Phase 3 study (Study 011) of migalastat HCl is ongoing and patients are being enrolled at 36 investigational sites worldwide.  A majority of the planned 60 patients have been enrolled in the study. The Company expects to complete enrollment in the first half of 2011 and to report top line results from this study in the second half of 2011.

Amicus and GSK intend to commence an additional Phase 3 study (Study 012) in t
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, ... Concepts (AMC), the largest multi-specialty Orthopedic, Spine and Neuro ... The award gives Bacterin ,pre-approved, ready-access to ...
... PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 ... announced a collaboration for the process development and cGMP ... used in Phase I and Phase II clinical trials. ... is prostatectomy, or removal of the prostate," noted David ...
Cached Medicine Technology:Bacterin Awarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. 2Goodwin Biotechnology Announces a Collaboration with Spectros Corporation 2
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been a ... is showing its latest designs of wedding dresses and launching ... company’s CEO, all the fresh new products are designed for ... to 80% off. All the clothes from LunaDress follow up ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ ... Alliance (PPHA). The PPHA's passion for others' well-being and ... greats, treated for obstructive sleep apnea (OSA) has propelled them ... in the valley. The most recent plans for an event ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... , , CHICAGO, July 21 ... new PLEX-ID system currently in development for detecting and characterizing ... in hospitals and other clinical sites. PLEX-ID is the next ... an innovative portfolio of instruments and tests the company is ...
... NORTH HOLLYWOOD, Calif., July 21 /PRNewswire-FirstCall/ -- IPC The Hospitalist ... group practice company, announced today that it will report results for the ... 6, 2009, after the market close. , , ... p.m. ET (2:00 p.m. PT) on August 6, 2009 and will be ...
... survey finds, , TUESDAY, July 21 (HealthDay News) -- Most ... individual health insurance policy on their own never end up ... according to a new study. , A report by the ... health policy reform, found that roughly three of every four ...
... , MINNEAPOLIS, July 21 Norwell VNA ... it has entered into a business relationship with Cardiocom ((R)) ... to patients with chronic illness. Cardiocom, the Experts in ... provider of award-winning telehealth solutions. , , ...
... - (Ocean Nutrition Canada) - These days, consumers ... dollars, buying products that are local, recycled, or ... is literally changing the world: If given the ... from certified sustainable sources, research from the US-based ...
... SAN DIEGO, July 21 The Department of ... the enterprise authentication tool for remote access to VA ... provide more veteran-centric benefit and healthcare services online. ... solution delivered through multiple channels without the cost and ...
Cached Medicine News:Health News:Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents 2Health News:IPC The Hospitalist Company, Inc. to Report Second Quarter 2009 Results 2Health News:Millions in U.S. Can't Afford Health Insurance 2Health News:Norwell VNA and Hospice Selects Cardiocom Telehealth as Its New Technology Vendor 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 3Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 4Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 5Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 6Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 2Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 3
... Powerful and Flexible Impact And Impact2 Pipettors ... volume ranges, our single channel Impact and ... of any application. Engineered with the same ... multichannel line, these pipettors are equally easy ...
... solution and best value in high ... action and ultra lightweight design reduce ... ejection with long, lever tip ejector, ... Accepts universal tips or for greater ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Inquire...
Medicine Products: